These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 25347203

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN, Baxter M, Chapagai D, Stafford JM, Nurmemmedov E, Altomare D, Wyatt MD, McInnes C.
    Eur J Med Chem; 2022 Jan 05; 227():113926. PubMed ID: 34735919
    [Abstract] [Full Text] [Related]

  • 23. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
    Yan F, Liu G, Chen T, Fu X, Niu MM.
    Molecules; 2019 Dec 27; 25(1):. PubMed ID: 31892137
    [Abstract] [Full Text] [Related]

  • 24. Pinning down the polo-box domain.
    Lee KS, Idle JR.
    Chem Biol; 2008 May 27; 15(5):415-6. PubMed ID: 18482691
    [Abstract] [Full Text] [Related]

  • 25. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
    Sakkiah S, Senese S, Yang Q, Lee KW, Torres JZ.
    PLoS One; 2014 May 27; 9(7):e101405. PubMed ID: 25036740
    [Abstract] [Full Text] [Related]

  • 26. Selectivity-determining residues in Plk1.
    Kothe M, Kohls D, Low S, Coli R, Rennie GR, Feru F, Kuhn C, Ding YH.
    Chem Biol Drug Des; 2007 Dec 27; 70(6):540-6. PubMed ID: 18005335
    [Abstract] [Full Text] [Related]

  • 27. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
    Shafique S, Bibi N, Rashid S.
    J Theor Biol; 2016 Jan 07; 388():72-84. PubMed ID: 26493360
    [Abstract] [Full Text] [Related]

  • 28. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
    Chen Y, Li Z, Liu Y, Lin T, Sun H, Yang D, Jiang C.
    Bioorg Chem; 2018 Dec 07; 81():278-288. PubMed ID: 30170276
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chem Biol; 2008 May 07; 15(5):459-66. PubMed ID: 18482698
    [Abstract] [Full Text] [Related]

  • 30. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
    Shakil S, Baig MH, Tabrez S, Rizvi SMD, Zaidi SK, Ashraf GM, Ansari SA, Khan AAP, Al-Qahtani MH, Abuzenadah AM, Chaudhary AG.
    Semin Cancer Biol; 2019 Jun 07; 56():47-55. PubMed ID: 29122685
    [Abstract] [Full Text] [Related]

  • 31. Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1.
    Murugan RN, Ahn M, Lee WC, Kim HY, Song JH, Cheong C, Hwang E, Seo JH, Shin SY, Choi SH, Park JE, Bang JK.
    PLoS One; 2013 Jun 07; 8(11):e80043. PubMed ID: 24223211
    [Abstract] [Full Text] [Related]

  • 32. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
    Qin T, Chen F, Zhuo X, Guo X, Yun T, Liu Y, Zhang C, Lai L.
    J Med Chem; 2016 Aug 11; 59(15):7089-96. PubMed ID: 27425654
    [Abstract] [Full Text] [Related]

  • 33. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M, Pydi SP, Sharma S, Singh TP, Kaur P.
    J Mol Graph Model; 2014 Jun 11; 51():104-12. PubMed ID: 24879322
    [Abstract] [Full Text] [Related]

  • 34. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
    Keppner S, Proschak E, Schneider G, Spänkuch B.
    ChemMedChem; 2009 Nov 11; 4(11):1806-9. PubMed ID: 19746360
    [No Abstract] [Full Text] [Related]

  • 35. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
    Lin TY, Min HP, Jiang C, Niu MM, Yan F, Xu LL, Di B.
    Bioorg Med Chem; 2018 Jul 23; 26(12):3429-3437. PubMed ID: 29807699
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
    Egert-Schmidt AM, Dreher J, Dunkel U, Kohfeld S, Preu L, Weber H, Ehlert JE, Mutschler B, Totzke F, Schächtele C, Kubbutat MH, Baumann K, Kunick C.
    J Med Chem; 2010 Mar 25; 53(6):2433-42. PubMed ID: 20170163
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
    Raab M, Sanhaji M, Pietsch L, Béquignon I, Herbrand AK, Süß E, Gande SL, Caspar B, Kudlinzki D, Saxena K, Sreeramulu S, Schwalbe H, Strebhardt K, Biondi RM.
    ACS Chem Biol; 2018 Aug 17; 13(8):1921-1931. PubMed ID: 29927572
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.